AN2 Therapeutics Announces Research Collaboration With GSK to Advance Boron-Based LeuRS-Inhibitors Targeting Tuberculosis (TB)

AN2 awarded third year of funding from Gates Foundation MENLO PARK, Calif. --(BUSINESS WIRE)--Nov. 10, 2025-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics through its boron chemistry platform, today announced a collaboration